C-RAY Therapeutics Reports Fruitful Engagements at BIO 2025, Gears Up for SNMMI Annual Meeting

C-RAY Achieves Breakthrough in Medical Isotope Production with China's First Fully Automated Zr-89 Process

C-RAY Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital

In November 2024, C-RAY Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C-RAY"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding $100 million.

Join Us at SNMMI 2025 in New Orleans!

Visit Us at SNMMI 2025 in New Orleans: Booth #2128